73 results
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
27 Mar 24
Regulation FD Disclosure
4:26pm
t i n o p a t h y P r o l i f e r a t i v e P D R D i a b e t i c R e t i n o p a t h y
DR Progression Can Have a Significant Impact On Functional
8-K
OCUP
Ocuphire Pharma Inc
5 Dec 23
Departure of Directors or Certain Officers
7:15pm
. Patel has 15 years of experience in medical research, including biotech R&D, and pharmaceutical business development. He has been in ophthalmology since
8-K
EX-99.1
OCUP
Ocuphire Pharma Inc
2 Nov 23
Ocuphire Corporate Presentation November 2023
8:44am
Mitch Brigell, PhD Head, Clinical Development and Strategy Daniela Oniciu, PhD Global Head, R&D, Chemistry and Product Development Ronil Patel, MTech
8-K
EX-99.1
otu ic12m
1 Aug 23
Restore Vision & Clarity Ocuphire Corporate Presentation August 2023
11:21am
8-K
EX-99.2
k15h1f3to gyo42pj
15 May 23
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
8:07am
8-K
EX-99.2
oldgn
12 Aug 22
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update
7:51am
8-K
EX-99.1
x7tzjknmf709lrm
19 May 22
Regulation FD Disclosure
7:43am
8-K
EX-99.1
e2je9y9km o8a
13 May 22
Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update
8:14am
8-K
EX-99.1
r2vce zwwifvsncb59
24 Mar 22
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update
8:17am
8-K
4m3w978x
31 Jan 22
Regulation FD Disclosure
9:53am
8-K
EX-99.1
twml554i89njx1a3r8
31 Jan 22
Regulation FD Disclosure
9:53am